Long-term follow-up (fu) of (Alliance) CALGB 40502/NCCTG N063H: a randomized phase iii trial of weekly paclitaxel (p) compared to weekly nanoparticle albumin bound nab-paclitaxel (np) or ixabepilone (ix) +/- bevacizumab (b) as first-line therapy for locally recurrent or metastatic breast cancer (MBC)
- Citation:
- Cancer Res vol 78 (4 Supplement ) GS3-06.
- Meeting Instance:
- SABCS 2017
- Year:
- 2018
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Long-Term-Followup
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10CA180820, U10CA180821, U10CA180882, U10CA180888; UG1CA189830
- Corr. Author:
- Authors:
- Hope S. Rugo William T. Barry Alvaro Moreno-Aspitia Alan Lyss Lucas Huebner Erica L. Mayer Michael Naughton RM Layman Lisa A. Carey RA Somer D Toppmeyer M Velasco Edith A. Perez Clifford Hudis Eric Winer
- Networks:
- CA136, HEARTLAND, LAPS-CT018, LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NY016, LAPS-TX035, NJ036, PR028
- Study
- CALGB-40502
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: